Unnamed stage
$8.6m
Nyrada raises $8.6M placement to fund Xolatryp heart trial
Australian biotech Nyrada has banked US$7.76 million through a share placement managed by Bell Potter, with proceeds going to its clinical pipeline, including the Phase IIa trial of Xolatryp in heart attack patients.